Pregled bibliografske jedinice broj: 1192414
Systematic biopsy should not be omitted in the era of combined magnetic resonance imaging/ultrasound fusion-guided biopsies of the prostate
Systematic biopsy should not be omitted in the era of combined magnetic resonance imaging/ultrasound fusion-guided biopsies of the prostate // International urology and nephrology, 53 (2021), 11; 2251-2259 doi:10.1007/s11255-021-02989-2 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1192414 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Systematic biopsy should not be omitted in the era of combined magnetic resonance
imaging/ultrasound fusion-guided biopsies of the prostate
(Systematic biopsy should not be omitted in the era
of combined magnetic resonance imaging/ultrasound
fusion-guided biopsies of the prostate)
Autori
Lodeta, Branimir ; Trkulja, Vladimir ; Kolroser-Sarmiento, Georg ; Jozipović, Danijel ; Salmhofer, Aigul ; Augustin, Herbert
Izvornik
International urology and nephrology (0301-1623) 53
(2021), 11;
2251-2259
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
fusion-guided prostate biopsy ; magnetic resonance imaging ; prostate cancer ; targeted prostate biopsy ; trans-rectal biopsy
Sažetak
Purpose: To evaluate prostate cancer detection rates with classical trans-rectal ultrasound- guided systematic 10-core biopsies (SB), targeted biopsies (TB) guided by magnetic resonance (MR)/US fusion imaging and their combination in biopsy- naïve and patients with previously negative prostate biopsies. We compared pathology results after radical prostatectomy with biopsy findings. Methods: Consecutive patients with prostate imaging-reporting and data system lesions grade ≥ 3 submitted to MRI/US-guided TB and subsequent standard 10-core SB between December 2015 and June 2019 were analyzed. Results: Detection rate (TB- or SB-positive) in 563 included patients (192 naïve, 371 with previous biopsies) was 56.7% (67.7% for the first, 50.9% for repeated biopsies). With TB (disregarding SB), the rates were 41.4%, 52.1% and 35.8%, respectively. With SB (disregarding TB), the rates were 49.1%, 63.0% and 41.8%, respectively. Eventually, 118 patients underwent surgery and clinically significant cancer was found in 111 (94.1%) specimens. Of those, 23 (20.7%) would have been missed had we relied upon a negative TB and 14 (12.6%) would have been missed had we relied upon a negative SB, disregarding a positive finding on the alternative biopsy template. Conclusion: SB should not be omitted since TB and SB combination have higher detection rate of clinically relevant prostate cancer than either procedure alone.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE